Cervical Cancer Market

DelveInsight's "Cervical Cancer Market Insights, Epidemiology, and Market Forecast-2030" report delivers an in-depth understanding of the Cervical Cancer, historical and forecasted epidemiology as well as the Cervical Cancer market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Cervical Cancer market report provides current treatment practices, emerging drugs, Cervical Cancer market share of the individual therapies, current and forecasted Cervical Cancer market Size from 2017 to 2030 segmented by seven major markets. The Report also covers current Cervical Cancer treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.


Geography Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan


Study Period: 2017-2030


Cervical Cancer Disease Understanding and Treatment Algorithm

Cervical cancer is one of the most common gynecological tumors that occur in the cells of the cervix. The most significant cause of cervical cancer is persistent papillomavirus infection. Gynecological cancers are among the most common cancers in women. Cervical cancer is the most common type of gynecological cancer. Indeed, it is one of the major public health problems in the world and one of the top causes for disability-adjusted life-years (DALYs). Yet, cervical cancer is one of the most preventable cancers. HPV is the most common sexually transmitted infection worldwide and is the cause of almost all cases of cervical cancer. Because precancerous lesions can be found by the Papanicolaou (Pap) test and treated and cured, cervical cancer is often detected before it becomes advanced.


Diagnosis 

This segment of the report covers the detailed diagnostic methods or tests for Cervical Cancer. 


Treatment 

The standard management of patients with early‐stage (FIGO stage IA‐IB1) cervical cancer is a radical hysterectomy and lymph node dissection and/or radiation with or without chemotherapy. The standard management of individuals with locally advanced cervical cancer includes external beam radiotherapy with concurrent cisplatin‐based chemotherapy with brachytherapy.


This chapter covers the details of conventional and current medical therapies available for the treatment of Cervical Cancer. It also provides Cervical Cancer treatment guidelines across the United States, Europe, and Japan. 


DelveInsight’s Cervical Cancer market report gives a thorough understanding of the disease by including details such as disease definition, symptoms, types, grading, pathophysiology, and diagnosis. It also provides Cervical Cancer treatment algorithms and treatment guidelines in the US, Europe, and Japan.

Cervical Cancer Epidemiology  

The Cervical Cancer epidemiology chapters provide insights about historical and current Cervical Cancer patient pool and forecasted trends for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. Cervical Cancer epidemiology is segmented by the Incident cases of Cervical Cancer, Stage-specific Incidence of Cervical Cancer, Histopathologic Types of Cervical Cancer, Age-specific cases of Cervical Cancer. Besides, the report includes a thorough analysis of all segments.


Key Findings

According to DelveInsight’s, the total prevalent population of Cervical Cancer in seven major markets was 43,514 in 2017. These cases are expected to increase with a significant CAGR during the study period (2017–2030).


Country Wise- Cervical Cancer Epidemiology 

Among all the seven major markets, total prevalent cases for Cervical Cancer were highest in the United States, followed by Japan and Germany. Spain accounted for the least number of prevalent cases among the 7MM. 

Cervical Cancer Drug Chapters

This segment encloses the detailed analysis of the drugs in the Cervical Cancer pipeline. It also helps understand the cervical cancer clinical trial details, expressive pharmacological action, agreements of the included drug, and the latest news and press releases.


Therapies administered for treatment of metastatic or recurrent cases comprises systemic therapies, which include paclitaxel plus cisplatin-based doublets or triplet combination therapies. Over the past three decades, these have remained the mainstay or standard of care (SOC) without vastly impacting the median overall survival (OS) of patients with stage IVB or recurrent disease despite multiple studies with single-agent or combination chemotherapy. FDA approved drugs include Avastin, Keytruda and Hycamtin.


Cervical Cancer Market Outlook

The market size of Cervical Cancer is expected to increase at a significant CAGR during the study period (2017–2030). Among all the seven major markets, the United States accounted for the largest Cervical Cancer market size. Among EU5 countries, Germany, in 2017, had the largest market size with USD 25.46 million, while Spain had the smallest market size of USD 0.34 million.


Cervical Cancer Drugs Uptake

This section focuses on the rate of uptake of the potential drugs in the Cervical Cancer market or expected to get launched in the market during the study period 2017–2030. The analysis covers Cervical Cancer market uptake by drugs; patient uptake by therapies; and sale of each drug.


It helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs based on market share and size. All of which will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.


Cemiplimab (Regeneron), Durvalumab (AstraZeneca), LN-145 (Iovance), Z-100 (Zeria Pharmaceutical), Tisotumab vedotin (Seattle Genetics/Genmab) are the major players that are going to alter the market dynamics in the coming years, during the forecasted period 2020-2030.


Cervical Cancer Pipeline Development Activities 

The report provides insights into different therapeutic candidates and also analyses the key players involved in developing targeted therapeutics.


Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing, patent details, and emerging therapies, concerning Cervical Cancer  


Reimbursement Scenario in Cervical Cancer

Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In a report, we take reimbursement into consideration to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy. 


KOL- Views 

To keep up with current market trends, we take KOLs and SME's opinion working in Cervical Cancer domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging therapies treatment patterns or Cervical Cancer market trend. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs. 


Competitive Intelligence Analysis 

We perform Competitive and Market Intelligence analysis of the Cervical Cancer Market by using various Competitive Intelligence tools that include - SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies etc. The inclusion of the analysis entirely depends upon the data availability.


Scope of the Report

  • The report covers the descriptive overview of Cervical Cancer, explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies
  • Comprehensive insight has been provided into the Cervical Cancer epidemiology and treatment in the 7MM
  • Additionally, an all-inclusive account of both the current and emerging therapies for Cervical Cancer are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
  • A detailed review of Cervical Cancer market; historical and forecasted is included in the report, covering drug outreach in the 7MM
  • The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Cervical Cancer market


Report Highlights

  • In the coming years, Cervical Cancer market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market
  • The companies and academics are working to assess challenges and seek opportunities that could influence Cervical Cancer R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition       
  • Major players are involved in developing therapies for Cervical Cancer. Launch of emerging therapies will significantly impact the Cervical Cancer market
  • A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for Cervical Cancer
  • Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities


Cervical Cancer Report Insights

  • Patient Population
  • Therapeutic Approaches
  • Cervical Cancer Pipeline Analysis
  • Cervical Cancer Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies


Cervical Cancer Report Key Strengths

  • 11 Years Forecast
  • 7MM Coverage 
  • Cervical Cancer Epidemiology Segmentation
  • Key Cross Competition 
  • Highly Analyzed Market
  • Drugs Uptake


Cervical Cancer Report Assessment

  • Current Treatment Practices
  • Unmet Needs
  • Pipeline Product Profiles
  • Market Attractiveness
  • Market Drivers and Barriers


Key Questions

Market Insights:

  • What was the Cervical Cancer market share (%) distribution in 2017 and how it would look like in 2030?
  • What would be the Cervical Cancer total market size as well as market size by therapies across the 7MM during the forecast period (2017-2030)?
  • What are the key findings pertaining to the market across 7MM and which country will have the largest Cervical Cancer market size during the forecast period (2017-2030)?
  • At what CAGR, the Cervical Cancer market is expected to grow in 7MM during the forecast period (2017-2030)?
  • What would be the Cervical Cancer market outlook across the 7MM during the forecast period (2017-2030)?
  • What would be the Cervical Cancer market growth till 2030, and what will be the resultant market Size in the year 2030?
  • How would the market drivers, barriers and future opportunities affect the market dynamics and subsequent analysis of the associated trends?

Epidemiology Insights:

  • What is the disease risk, burden and unmet needs of the Cervical Cancer?
  • What is the historical Cervical Cancer patient pool in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
  • What would be the forecasted patient pool of Cervical Cancer in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
  • What will be the growth opportunities in the 7MM with respect to the patient population pertaining to Cervical Cancer?
  • Out of all 7MM countries, which country would have the highest prevalent population of Cervical Cancer during the forecast period (2017-2030)?
  • At what CAGR the population is expected to grow in 7MM during the forecast period (2017-2030)?


Current Treatment Scenario, Marketed Drugs and Emerging Therapies:

  • What are the current options for the Cervical Cancer treatment, along with the approved therapy?
  • What are the current treatment guidelines for the treatment of Cervical Cancer in the USA, Europe, and Japan?
  • What are the Cervical Cancer marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety and efficacy, etc.?
  • How many companies are developing therapies for the treatment of Cervical Cancer?
  • How many therapies are developed by each company for Cervical Cancer treatment?
  • How many are emerging therapies in mid-stage, and late stage of development for Cervical Cancer treatment?
  • What are the key collaborations (Industry - Industry, Industry - Academia), Mergers and acquisitions, licensing activities related to the Cervical Cancer therapies? 
  • What are the recent novel therapies, targets, mechanisms of action and technologies developed to overcome the limitation of existing therapies? 
  • What are the clinical studies going on for Cervical Cancer and their status?
  • What are the key designations that have been granted for the emerging therapies for Cervical Cancer?
  • What are the global historical and forecasted market of Cervical Cancer?


Reasons to buy

  • The report will help in developing business strategies by understanding trends shaping and driving the Cervical Cancer market
  • To understand the future market competition in the Cervical Cancer market and Insightful review of the key market drivers and barriers
  • Organize sales and marketing efforts by identifying the best opportunities for Cervical Cancer in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom) and Japan
  • Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
  • Organize sales and marketing efforts by identifying the best opportunities for Cervical Cancer market
  • To understand the future market competition in the Cervical Cancer market


Which geography accounted for the largest Cervical Cancer market size?

The United States accounted for the largest Cervical Cancer market size.


What is forecasted Cervical Cancer size in 2030?

DelveInsight estimates an increase in Cervical Cancer Market Size during the study period, 2017–2030


What are the present Cervical Cancer market drivers?

Advancements in treatment, improvement in preventive measures, early detection of disease, therapies in development for recurrent and relapsed cases.


What are the Cervical Cancer market barriers?

Insufficient data on disease biomarkers, barriers in screening, access to palliative care, costs associated with treatment


How many companies are developing drugs for Cervical Cancer?

Currently, six key pharma players are developing the drug for Cervical Cancer    


Which are the leading companies in Cervical Cancer market?

Key Players – Regeneron, AstraZeneca, LN-145, Zeria Pharmaceutical, Seattle Genetics/Genmab, Advaxis


How is epidemiology segmented for Cervical Cancer?

Incident cases of Cervical Cancer, Stage-specific Incidence of Cervical Cancer, Histopathologic Types of Cervical Cancer, Age-specific cases of Cervical Cancer

1 Key Insights

2 Executive Summary of Cervical Cancer

3 SWOT Analysis for Cervical Cancer

4 Cervical Cancer Epidemiology Overview at a Glance

4.1 Patient Share (%) Distribution of Cervical Cancer in 2017

4.2 Patient Share (%) Distribution of Cervical Cancer in 2030

5 Cervical Cancer Market Overview at a Glance

5.1 Market Share (%) Distribution of Cervical Cancer in 2017

5.2 Market Share (%) Distribution of Cervical Cancer in 2030

6 Disease Background and Overview

6.1 Introduction

6.2 Definition

6.3 Etiology

6.4 Risk factors

6.5 Staging

6.6 Pathophysiology

6.7 Diagnosis

Forty-year timeline of public health research and policy on HPV and cervical cancer

7 Epidemiology and Patient Population

7.1 Key Findings

7.2 Total Incident Population of Cervical Cancer in 7MM

7.3 Assumption and Rationale: 7MM

8 Country Wise-Epidemiology of Cervical Cancer

8.1 The United States

8.1.1 Incident cases of Cervical Cancer in the United States

8.1.2 Stage-specific Incidence of Cervical Cancer in the United States

8.1.3 Histopathologic Types of Cervical Cancer in the United States

8.1.4 Age-specific cases of Cervical Cancer in the United States

8.2 Germany

8.2.1 Incident cases of Cervical Cancer in Germany

8.2.2 Stage-specific Incidence of Cervical Cancer in Germany

8.2.3 Histopathologic Types of Cervical Cancer in Germany

8.2.4 Age-specific cases of Cervical Cancer in Germany

8.3 France

8.3.1 Incident cases of Cervical Cancer in France

8.3.2 Stage-specific Incidence of Cervical Cancer in France

8.3.3 Histopathologic Types of Cervical Cancer in France

8.3.4 Age-specific cases of Cervical Cancer in France

8.4 Italy

8.4.1 Incident cases of Cervical Cancer in Italy

8.4.2 Stage-specific Incidence of Cervical Cancer in Italy

8.4.3 Histopathologic Types of Cervical Cancer in Italy

8.4.4 Age-specific cases of Cervical Cancer in Italy

8.5 Spain

8.5.1 Incident cases of Cervical Cancer in Spain

8.5.2 Stage-specific Incidence of Cervical Cancer in Spain

8.5.3 Histopathologic Types of Cervical Cancer in Spain

8.5.4 Age-specific cases of Cervical Cancer in Spain

8.6 The United Kingdom

8.6.1 Incident cases of Cervical Cancer in the United Kingdom

8.6.2 Stage-specific Incidence of Cervical Cancer in the United Kingdom

8.6.3 Histopathologic Types of Cervical Cancer in the United Kingdom

8.6.4 Age-specific cases of Cervical Cancer in the United Kingdom

8.7 Japan

8.7.1 Incident cases of Cervical Cancer in Japan

8.7.2 Stage-specific Incidence of Cervical Cancer in Japan

8.7.3 Histopathologic Types of Cervical Cancer in Japan

8.7.4 Age-specific cases of Cervical Cancer in Japan

9 Treatment and Management

9.1 Side effects of treatment

9.2 Prevention of Cervical cancer

9.3 Guidelines

9.3.1 NCCN Guidelines

9.3.2 ESMO guidelines

9.3.3 Japan Society of Gynecologic Oncology (JSGO) Guidelines

9.4 Patient Journey

10 Unmet Needs

11 Marketed Therapies

11.1 Avastin (Bevacizumab): Genentech/Roche

11.1.1 Product Description

11.1.2 Regulatory Milestones

11.1.3 Other developmental activities

11.1.4 Clinical Development

11.1.4.1 Clinical Trials Information

11.1.5 Safety and Efficacy

11.1.6 Product Profile

11.2 Avastin Biosimilars

11.2.1 Mvasi: Amgen/Allergan

11.2.1.1 Product Description

11.2.1.2 Regulatory Milestones

11.2.1.3 Other developmental activities

11.2.2 Zirabev: Pfizer

11.2.2.1 Product Description

11.2.2.2 Regulatory Milestones

11.2.3 Aybintio: Samsung Bioepis

11.2.3.1 Product Description

11.2.3.2 Regulatory Milestones

11.3 Hycamtin (Topotecan Hydrochloride): GlaxoSmithKline/Novartis

11.3.1 Product Description

11.3.2 Regulatory Milestones

11.3.3 Other developmental activities

11.3.4 Clinical Development

11.3.4.1 Clinical Trials Information

11.3.5 Safety and Efficacy

11.3.6 Product Profile

11.4 Keytruda (Pembrolizumab): Merck Sharp & Dohme

11.4.1 Product Description

11.4.2 Regulatory Milestones

11.4.3 Clinical Development

11.4.3.1 Clinical Trials Information

11.4.4 Safety and Efficacy

11.4.5 Product Profile

12 Emerging Therapies

12.1 Tisotumab vedotin: Seattle Genetics/ Genmab

12.1.1 Product Description

12.1.2 Product Development Activities

12.1.3 Clinical Development

12.1.3.1 Clinical Trial Information

12.1.4 Safety and Efficacy

12.2 Durvalumab: AstraZeneca

12.2.1 Product Description

12.2.2 Product Development Activities

12.2.3 Clinical Development

12.2.3.1 Clinical Trial Information

12.3 Z-100: Zeria Pharmaceutical

12.3.1 Product Description

12.3.2 Clinical Development

12.3.2.1 Clinical Trial Information

12.3.3 Safety and Efficacy

12.4 Cemiplimab: Regeneron Pharmaceutical/Sanofi

12.4.1 Product Description

12.4.2 Product Development Activities

12.4.3 Clinical Development

12.4.3.1 Clinical Trial Information

12.4.4 Safety and Efficacy

12.5 ADXS11-001: Advaxis

12.5.1 Product Description

12.5.2 Product Development Activities

12.5.3 Clinical Development

12.5.3.1 Clinical Trial Information

12.6 LN-145: Iovance Biotherapeutics

12.6.1 Product Description

12.6.2 Product Development Activities

12.6.3 Clinical Development

12.6.3.1 Clinical Trial Information

12.6.4 Safety and Efficacy

13 Other Promising Therapies

13.1 Balstilimab + Zalifrelimab: Agenus

13.1.1 Product Description

13.1.2 Product Development Activities

13.1.3 Clinical Development

13.1.3.1 Clinical Trial Information

13.1.4 Safety and Efficacy

13.2 Tiragolumab: Roche

13.2.1 Product Description

13.3 AK104: Akeso Biopharma

13.3.1 Product Description

13.4 Trastuzumab Deruxtecan: AstraZeneca

13.4.1 Product Description

13.5 VB10.16 + Atezolizumab: Vaccibody/ Roche

13.5.1 Product Description

13.6 RO6874281: Roche

13.6.1 Product Description

13.7 ALT 803: Altor BioScience

13.7.1 Product Description

13.8 Balstilimab: Agenus

13.8.1 Product Description

14 Cervical Cancer: 7 Major Market Analysis

14.1 Key Findings

14.2 Market Size of Cervical Cancer in 7MM

14.3 Market Outlook – 7MM

15 Country-Wise Market Analysis

15.1 The United States

15.1.1 Total Market size of Cervical Cancer

15.1.2 Cervical Cancer Market Size by Therapies

15.1.2.1 Market Size of Therapies for Locally Advanced Cervical Cancer

15.1.2.2 Market Size of Metastatic Cervical Cancer by 1st LoT

15.1.2.3 Market Size of Metastatic Cervical Cancer by 2nd LoT

15.2 EU5 Countries

15.2.1 Germany

15.2.1.1 Total Market size of Cervical Cancer

15.2.1.2 Cervical Cancer Market Size by Therapies

15.2.1.2.1 Market Size of Therapies for Locally Advanced Cervical Cancer

15.2.1.2.2 Market Size of Metastatic Cervical Cancer by 1st LoT

15.2.1.2.3 Market Size of Metastatic Cervical Cancer by 2nd LoT

15.2.2 France

15.2.2.1 Total Market size of Cervical Cancer

15.2.2.2 Cervical Cancer Market Size by Therapies

15.2.2.2.1 Market Size of Therapies for Locally Advanced Cervical Cancer

15.2.2.2.2 Market Size of Metastatic Cervical Cancer by 1st LoT

15.2.2.2.3 Market Size of Metastatic Cervical Cancer by 2nd LoT

15.2.3 Italy

15.2.3.1 Total Market size of Cervical Cancer

15.2.3.2 Cervical Cancer Market Size by Therapies

15.2.3.2.1 Market Size of Therapies for Locally Advanced Cervical Cancer

15.2.3.2.2 Market Size of Metastatic Cervical Cancer by 1st LoT

15.2.3.2.3 Market Size of Metastatic Cervical Cancer by 2nd LoT

15.2.4 Spain

15.2.4.1 Total Market size of Cervical Cancer

15.2.4.2 Cervical Cancer Market Size by Therapies

15.2.4.2.1 Market Size of Therapies for Locally Advanced Cervical Cancer

15.2.4.2.2 Market Size of Metastatic Cervical Cancer by 1st LoT

15.2.4.2.3 Market Size of Metastatic Cervical Cancer by 2nd LoT

15.2.5 The UK

15.2.5.1 Total Market size of Cervical Cancer

15.2.5.2 Cervical Cancer Market Size by Therapies

15.2.5.2.1 Market Size of Therapies for Locally Advanced Cervical Cancer

15.2.5.2.2 Market Size of Metastatic Cervical Cancer by 1st LoT

15.2.5.2.3 Market Size of Metastatic Cervical Cancer by 2nd LoT

15.3 Japan

15.3.1 Total Market size of Cervical Cancer

15.3.2 Cervical Cancer Market Size by Therapies

15.3.2.1 Market Size of Therapies for Locally Advanced Cervical Cancer

15.3.2.2 Market Size of Metastatic Cervical Cancer by 1st LoT

15.3.2.3 Market Size of Metastatic Cervical Cancer by 2nd LoT

16 Market Drivers

17 Market Barriers

18 Appendix

18.1 Report Methodology

19 DelveInsight Capabilities

20 Disclaimer

21 About DelveInsight

List of Table:

Table 1: Summary of Cervical Cancer Market, Epidemiology, and Key Events (2017–2030)

Table 2: Total cases of Cervical Cancer in 7MM (2017-2030)

Table 3: Incident cases of Cervical Cancer in the United States (2017-2030)

Table 4: Stage Specific Incidence of Cervical Cancer in the United States(2017-2030)

Table 5: Histopathologic Types of Cervical Cancer in the United States(2017-2030)

Table 6: Age specific cases of Cervical Cancer in the United States(2017-2030)

Table 7: Incident cases of Cervical Cancer in Germany (2017-2030)

Table 8: Stage Specific Incidence of Cervical Cancer in Germany(2017-2030)

Table 9: Histopathologic Types of Cervical Cancer in Germany(2017-2030)

Table 10: Age specific cases of Cervical Cancer in Germany(2017-2030)

Table 11: Incident cases of Cervical Cancer in France (2017-2030)

Table 12: Stage Specific Incidence of Cervical Cancer in France(2017-2030)

Table 13: Histopathologic Types of Cervical Cancer in France(2017-2030)

Table 14: Age specific cases of Cervical Cancer in France(2017-2030)

Table 15: Incident cases of Cervical Cancer in Italy (2017-2030)

Table 16: Stage Specific Incidence of Cervical Cancer in Italy(2017-2030)

Table 17: Histopathologic Types of Cervical Cancer in Italy(2017-2030)

Table 18: Age specific cases of Cervical Cancer in Italy(2017-2030)

Table 19: Incident cases of Cervical Cancer in Spain (2017-2030)

Table 20: Stage Specific Incidence of Cervical Cancer in Spain(2017-2030)

Table 21: Histopathologic Types of Cervical Cancer in Spain(2017-2030)

Table 22: Age specific cases of Cervical Cancer in Spain(2017-2030)

Table 23: Incident cases of Cervical Cancer in the United Kingdom (2017-2030)

Table 24: Stage Specific Incidence of Cervical Cancer in the United Kingdom(2017-2030)

Table 25: Histopathologic Types of Cervical Cancer in the United Kingdom(2017-2030)

Table 26: Age specific cases of Cervical Cancer in the United Kingdom(2017-2030)

Table 27: Incident cases of Cervical Cancer in Japan (2017-2030)

Table 28: Stage Specific Incidence of Cervical Cancer in Japan(2017-2030)

Table 29: Histopathologic Types of Cervical Cancer in Japan(2017-2030)

Table 30: Age specific cases of Cervical Cancer in Japan(2017-2030)

Table 31: Avastin, Clinical Trial Description, 2020

Table 32: Hycamtin, Clinical Trial Description, 2020

Table 33: Keytruda, Clinical Trial Description, 2020

Table 34: Tisotumab Vedotin , Clinical Trial Description, 2020

Table 35: Z-100, Clinical Trial Description, 2020

Table 36: Cemiplimab , Clinical Trial Description, 2020

Table 37: ADXS11-001, Clinical Trial Description, 2020

Table 38: LN-145 , Clinical Trial Description, 2020

Table 39: Balstilimab + Zalifrelimab, Clinical Trial Description, 2020

Table 40: 7 Major Market Size of Cervical Cancer in USD Million (2017–2030)

Table 41: The US Market size of Cervical Cancer in USD Million (2017–2030)

Table 42: The US market size of Therapies for Locally Advanced Cervical Cancer in USD Million (2017–2030)

Table 43: The US market size of Metastatic Cervical Cancer by 1st LoT in USD Million (2017–2030)

Table 44: The US market size of Metastatic Cervical Cancer by 2nd LoT in USD Million (2017–2030)

Table 45: Germany Market size of Cervical Cancer in USD Million (2017–2030)

Table 46: Germany market size of Therapies for Locally Advanced Cervical Cancer in USD Million (2017–2030)

Table 47: Germany market size of Metastatic Cervical Cancer by 1st LoT in USD Million (2017–2030)

Table 48: Germany market size of Metastatic Cervical Cancer by 2nd LoT in USD Million (2017–2030)

Table 49: France Market size of Cervical Cancer in USD Million (2017–2030)

Table 50: France market size of Therapies for Locally Advanced Cervical Cancer in USD Million (2017–2030)

Table 51: France market size of Metastatic Cervical Cancer by 1st LoT in USD Million (2017–2030)

Table 52: France market size of Cervical Cancer by Therapies in USD Million (2017–2030)

Table 53: Italy Market size of Cervical Cancer in USD Million (2017–2030)

Table 54: Italy market size of Therapies for Locally Advanced Cervical Cancer in USD Million (2017–2030)

Table 55: Italy market size of Metastatic Cervical Cancer by 1st LoT in USD Million (2017–2030)

Table 56: Italy market size of Metastatic Cervical Cancer by 2nd LoT in USD Million (2017–2030)

Table 57: Spain Market size of Cervical Cancer in USD Million (2017–2030)

Table 58: Spain market size of Therapies for Locally Advanced Cervical Cancer in USD Million (2017–2030)

Table 59: Spain market size of Metastatic Cervical Cancer by 1st LoT in USD Million (2017–2030)

Table 60: Spain market size of Metastatic Cervical Cancer by 2nd LoT in USD Million (2017–2030)

Table 61: The UK Market size of Cervical Cancer in USD Million (2017–2030)

Table 62: The UK market size of Therapies for Locally Advanced Cervical Cancer in USD Million (2017–2030)

Table 63: The UK market size of Metastatic Cervical Cancer by 1st LoT in USD Million (2017–2030)

Table 64: The UK market size of Metastatic Cervical Cancer by 2nd LoT in USD Million (2017–2030)

Table 65: Japan Market size of Cervical Cancer in USD Million (2017–2030)

Table 66: Japan market size of Therapies for Locally Advanced Cervical Cancer in USD Million (2017–2030)

Table 67: Japan market size of Metastatic Cervical Cancer by 1st LoT in USD Million (2017–2030)

Table 68: Japan market size of Metastatic Cervical Cancer by 2nd LoT in USD Million (2017–2030)



List of Figure:

Figure 1: SWOT Analysis

Figure 2: Terminology of cervical disease categories

Figure 3: Risk factors for cervical cancer

Figure 4: Risk factors for cervical cancer

Figure 5: Risk factors for cervical cancer

Figure 6: Timeline of public health research and policy of HPV and cervical cancer

Figure 7: Total Incident cases of Cervical Cancer in 7MM (2017-2030)

Figure 8: Incident cases of Cervical Cancer in the United States (2017-2030)

Figure 9: Stage Specific Incidence of Cervical Cancer in the United States (2017-2030)

Figure 10: Histopathologic Types of Cervical Cancer in the United States (2017-2030)

Figure 11: Age specific cases of Cervical Cancer in the United States (2017-2030)

Figure 12: Incident cases of Cervical Cancer in Germany (2017-2030)

Figure 13: Stage Specific Incidence of Cervical Cancer in Germany (2017-2030)

Figure 14: Histopathologic Types of Cervical Cancer in Germany (2017-2030)

Figure 15: Age specific cases of Cervical Cancer in Germany (2017-2030)

Figure 16: Incident cases of Cervical Cancer in France (2017-2030)

Figure 17: Stage Specific Incidence of Cervical Cancer in France (2017-2030)

Figure 18: Histopathologic Types of Cervical Cancer in France (2017-2030)

Figure 19: Age specific cases of Cervical Cancer in France (2017-2030)

Figure 20: Incident cases of Cervical Cancer in Italy (2017-2030)

Figure 21: Stage Specific Incidence of Cervical Cancer in Italy (2017-2030)

Figure 22: Histopathologic Types of Cervical Cancer in Italy (2017-2030)

Figure 23: Age specific cases of Cervical Cancer in Italy (2017-2030)

Figure 24: Incident cases of Cervical Cancer in Spain (2017-2030)

Figure 25: Stage Specific Incidence of Cervical Cancer in Spain (2017-2030)

Figure 26: Histopathologic Types of Cervical Cancer in Spain (2017-2030)

Figure 27: Age specific cases of Cervical Cancer in Spain (2017-2030)

Figure 28: Incident cases of Cervical Cancer in the United Kingdom (2017-2030)

Figure 29: Stage Specific Incidence of Cervical Cancer in the United Kingdom (2017-2030)

Figure 30: Histopathologic Types of Cervical Cancer in the United Kingdom (2017-2030)

Figure 31: Age specific cases of Cervical Cancer in the United Kingdom (2017-2030)

Figure 32: Incident cases of Cervical Cancer in Japan (2017-2030)

Figure 33: Stage Specific Incidence of Cervical Cancer in Japan (2017-2030)

Figure 34: Histopathologic Types of Cervical Cancer in Japan (2017-2030)

Figure 35: Age specific cases of Cervical Cancer in Japan (2017-2030)

Figure 36: Surgical treatment options for cervical cancer

Figure 37: Radiation treatment options for cervical cancer

Figure 38: Chemotherapy treatment options for cervical cancer

Figure 39: Workup for cervical cancer

Figure 40:  Primary treatment for cervical cancer

Figure 41: Primary treatment for cervical cancer

Figure 42: Primary treatment for cervical cancer

Figure 43: Adjuvant treatment of cervical cancer

Figure 44: Patient Journey of Cervical Cancer

Figure 45: Unmet needs for cervical cancer

Figure 46: 7 Major Market Size of Cervical Cancer in USD Million (2017–2030)

Figure 47: Market Size of Cervical Cancer in the United States, USD Millions (2017–2030)

Figure 48: The U.S. market size for Locally Advanced Cervical Cancer in USD Million (2017–2030)

Figure 49: The U.S. market size of Metastatic Cervical Cancer by 1st LoT in USD Million (2017–2030)

Figure 50: The U.S. market size of Metastatic Cervical Cancer by 2nd LoT in USD Million (2017–2030)

Figure 51: Market Size of Cervical Cancer in Germany, USD Millions (2017–2030)

Figure 52: Germany market size of Therapies for Locally Advanced Cervical Cancer in USD Million (2017–2030)

Figure 53: Germany market size of Metastatic Cervical Cancer by 1st LoT in USD Million (2017–2030)

Figure 54: Germany market size of Metastatic Cervical Cancer by 2nd LoT in USD Million (2017–2030)

Figure 55: Market Size of Cervical Cancer in France, USD Millions (2017–2030)

Figure 56: France market size of Therapies for Locally Advanced Cervical Cancer in USD Million (2017–2030)

Figure 57: France market size of Metastatic Cervical Cancer by 1st LoT in USD Million (2017–2030)

Figure 58: France market size of Cervical Cancer by therapies in USD Million (2017–2030)

Figure 59: Market Size of Cervical Cancer in Italy, USD Millions (2017–2030)

Figure 60: Italy market size of Therapies for Locally Advanced Cervical Cancer in USD Million (2017–2030)

Figure 61: Italy market size of Metastatic Cervical Cancer by 1st LoT in USD Million (2017–2030)

Figure 62: Italy market size of Metastatic Cervical Cancer by 2nd LoT in USD Million (2017–2030)

Figure 63: Market Size of Cervical Cancer in Spain, USD Millions (2017–2030)

Figure 64: Spain market size of Therapies for Locally Advanced Cervical Cancer in USD Million (2017–2030)

Figure 65: Spain market size of Metastatic Cervical Cancer by 1st LoT in USD Million (2017–2030)

Figure 66: Spain market size of Metastatic Cervical Cancer by 2nd LoT in USD Million (2017–2030)

Figure 67: Market Size of Cervical Cancer in the UK, USD Millions (2017–2030)

Figure 68: The U.K. market size of Therapies for Locally Advanced Cervical Cancer in USD Million (2017–2030)

Figure 69: The U.K. market size of Metastatic Cervical Cancer by 1st LoT in USD Million (2017–2030)

Figure 70: The U.K. market size of Metastatic Cervical Cancer by 2nd LoT in USD Million (2017–2030)

Figure 71: Market Size of Cervical Cancer in Japan, USD Millions (2017–2030)

Figure 72: Japan market size of Therapies for Locally Advanced Cervical Cancer in USD Million (2017–2030)

Figure 73: Japan market size of Metastatic Cervical Cancer by 1st LoT in USD Million (2017–2030)

Figure 74: Japan market size of Metastatic Cervical Cancer by 2nd LoT in USD Million (2017–2030)

Figure 75: Market drivers for Cervical cancer

Figure 76: Market Barriers for Cervical cancer

  • Tags:
  • Cervical Cancer market
  • Cervical Cancer market research
  • Cervical Cancer market insight
  • Cervical Cancer market trends
  • Cervical Cancer market forecast
  • Cervical Cancer market share
  • Cervical Cancer pipeline drugs
  • Cervical Cancer treatment algorithm
  • Cervical Cancer drugs
  • Cervical Cancer sales forecasting
  • Cervical Cancer market size
  • Cervical Cancer disease
  • Cervical Cancer epidemiology
  • Cervical Cancer

Forward to Friend

Need A Quote